SMN1 and proximal spinal muscular atrophy: Another disease that benefited from novel splice-modulating oligonucleotide drugs is spinal muscular atrophy (SMA), a neuromuscular genetic disorder primarily caused by mutation/deletion of the SMN1 gene, resulting in the production of a non-functional protein from this mutant gene.